405 related articles for article (PubMed ID: 26143158)
1. CCR5Δ32 mutation and HIV infection: basis for curative HIV therapy.
Allers K; Schneider T
Curr Opin Virol; 2015 Oct; 14():24-9. PubMed ID: 26143158
[TBL] [Abstract][Full Text] [Related]
2. Designer Nucleases: Gene-Editing Therapies using CCR5 as an Emerging Target in HIV.
Almeida MJ; Matos A
Curr HIV Res; 2019; 17(5):306-323. PubMed ID: 31652113
[TBL] [Abstract][Full Text] [Related]
3. Gene editing using a zinc-finger nuclease mimicking the CCR5Δ32 mutation induces resistance to CCR5-using HIV-1.
Badia R; Riveira-Muñoz E; Clotet B; Esté JA; Ballana E
J Antimicrob Chemother; 2014 Jul; 69(7):1755-9. PubMed ID: 24651827
[TBL] [Abstract][Full Text] [Related]
4. CCR5-targeted hematopoietic stem cell gene approaches for HIV disease: current progress and future prospects.
Lai Y
Curr Stem Cell Res Ther; 2012 Jul; 7(4):310-7. PubMed ID: 22486585
[TBL] [Abstract][Full Text] [Related]
5. CCR5 Δ32 homozygous cord blood allogeneic transplantation in a patient with HIV: a case report.
Duarte RF; Salgado M; Sánchez-Ortega I; Arnan M; Canals C; Domingo-Domenech E; Fernández-de-Sevilla A; González-Barca E; Morón-López S; Nogues N; Patiño B; Puertas MC; Clotet B; Petz LD; Querol S; Martinez-Picado J
Lancet HIV; 2015 Jun; 2(6):e236-42. PubMed ID: 26423196
[TBL] [Abstract][Full Text] [Related]
6. Multivalent anti-CCR ribozymes for stem cell-based HIV type 1 gene therapy.
Bai J; Rossi J; Akkina R
AIDS Res Hum Retroviruses; 2001 Mar; 17(5):385-99. PubMed ID: 11282007
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of a 32 bp deletion in the gene for human immunodeficiency virus 1 co-receptor CCR5 in Slovak population.
Takácová M; Nogová P; Hábeková M; Staneková D
Acta Virol; 2008; 52(4):261-4. PubMed ID: 19143484
[TBL] [Abstract][Full Text] [Related]
8. CCR5 Targeted Cell Therapy for HIV and Prevention of Viral Escape.
Hütter G; Bodor J; Ledger S; Boyd M; Millington M; Tsie M; Symonds G
Viruses; 2015 Jul; 7(8):4186-203. PubMed ID: 26225991
[TBL] [Abstract][Full Text] [Related]
9. Editing CCR5: a novel approach to HIV gene therapy.
Cornu TI; Mussolino C; Bloom K; Cathomen T
Adv Exp Med Biol; 2015; 848():117-30. PubMed ID: 25757618
[TBL] [Abstract][Full Text] [Related]
10. Coreceptor-Based Hematopoietic Stem Cell Gene Therapy for HIV Disease.
Hu J; Feng Y; Ma P; Lai Y
Curr Stem Cell Res Ther; 2019; 14(7):591-597. PubMed ID: 31120000
[TBL] [Abstract][Full Text] [Related]
11. Autologous Hematopoietic Stem Cells transplantation and genetic modification of CCR5 m303/m303 mutant patient for HIV/AIDS.
Esmaeilzadeh A; Farshbaf A; Erfanmanesh M
Med Hypotheses; 2015 Mar; 84(3):216-8. PubMed ID: 25613565
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation.
Gupta RK; Abdul-Jawad S; McCoy LE; Mok HP; Peppa D; Salgado M; Martinez-Picado J; Nijhuis M; Wensing AMJ; Lee H; Grant P; Nastouli E; Lambert J; Pace M; Salasc F; Monit C; Innes AJ; Muir L; Waters L; Frater J; Lever AML; Edwards SG; Gabriel IH; Olavarria E
Nature; 2019 Apr; 568(7751):244-248. PubMed ID: 30836379
[TBL] [Abstract][Full Text] [Related]
13. CCR5 as a natural and modulated target for inhibition of HIV.
Burke BP; Boyd MP; Impey H; Breton LR; Bartlett JS; Symonds GP; Hütter G
Viruses; 2013 Dec; 6(1):54-68. PubMed ID: 24381033
[TBL] [Abstract][Full Text] [Related]
14. Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation.
Allers K; Hütter G; Hofmann J; Loddenkemper C; Rieger K; Thiel E; Schneider T
Blood; 2011 Mar; 117(10):2791-9. PubMed ID: 21148083
[TBL] [Abstract][Full Text] [Related]
15. Rapid Rebound of a Preexisting CXCR4-tropic Human Immunodeficiency Virus Variant After Allogeneic Transplantation With CCR5 Δ32 Homozygous Stem Cells.
Verheyen J; Thielen A; Lübke N; Dirks M; Widera M; Dittmer U; Kordelas L; Däumer M; de Jong DCM; Wensing AMJ; Kaiser R; Nijhuis M; Esser S
Clin Infect Dis; 2019 Feb; 68(4):684-687. PubMed ID: 30020413
[TBL] [Abstract][Full Text] [Related]
16. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.
Hütter G; Nowak D; Mossner M; Ganepola S; Müssig A; Allers K; Schneider T; Hofmann J; Kücherer C; Blau O; Blau IW; Hofmann WK; Thiel E
N Engl J Med; 2009 Feb; 360(7):692-8. PubMed ID: 19213682
[TBL] [Abstract][Full Text] [Related]
17. TALENs-mediated homozygous CCR5Δ32 mutations endow CD4+ U87 cells with resistance against HIV‑1 infection.
Yu AQ; Ding Y; Lu ZY; Hao YZ; Teng ZP; Yan SR; Li DS; Zeng Y
Mol Med Rep; 2018 Jan; 17(1):243-249. PubMed ID: 29115572
[TBL] [Abstract][Full Text] [Related]
18. CCR5-edited gene therapies for HIV cure: Closing the door to viral entry.
Haworth KG; Peterson CW; Kiem HP
Cytotherapy; 2017 Nov; 19(11):1325-1338. PubMed ID: 28751153
[TBL] [Abstract][Full Text] [Related]
19. Restriction of HIV type 1 infection in macrophages heterozygous for a deletion in the CC-chemokine receptor 5 gene.
Ometto L; Zanchetta M; Cabrelle A; Esposito G; Mainardi M; Chieco-Bianchi L; De Rossi A
AIDS Res Hum Retroviruses; 1999 Nov; 15(16):1441-52. PubMed ID: 10555107
[TBL] [Abstract][Full Text] [Related]
20. A simultaneous knockout knockin genome editing strategy in HSPCs potently inhibits CCR5- and CXCR4-tropic HIV-1 infection.
Dudek AM; Feist WN; Sasu EJ; Luna SE; Ben-Efraim K; Bak RO; Cepika AM; Porteus MH
Cell Stem Cell; 2024 Apr; 31(4):499-518.e6. PubMed ID: 38579682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
